Astal Laboratories
Astal Laboratories (ASTALLTD) share price was ₹65.94 at the 28 Oct 2026 close; market capitalisation ₹289 Cr; P/E (TTM) 7.17; sector Commercial Services. The share price fell 34.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹100.94 Cr and net profit was ₹9.42 Cr. Promoters held 4.59% of Astal Laboratories in Sep 2026, up 0.06 percentage points from Jun 2026. Its Tapetide Score is 58/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapCommercial ServicesServicesPrice-based figures as of 28 Oct 2026, 15:30 IST · TTM
Peer Comparison
Healthcare › Commercial Services › Trading & Distributors › Pharmaceuticals
| ₹1,766.80 | 35.05 | 4,23,915 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,636.00 | 87.46 | 2,55,806 Cr | 15.26 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,595.60 | 72.14 | 1,74,802 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,184.30 | 107.92 | 1,18,020 Cr | 22.27 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,181.00 | 26.28 | 1,17,805 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,341.00 | 34.73 | 1,11,931 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.40 | 32.83 | 1,10,709 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Astal Laboratories (this company) | — | 7.17 | 289 Cr | 0.85 | 0.00% | 4.41% | 5.58% | 311 Cr | 22 Cr |
| Median 8 companies | ₹1,766.80 | 34.89 | 1,17,913 Cr | 4.71 | 0.47% | 12.98% | 16.41% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.81 times its book value
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 4.59%
- Company has high debtors of 229 days.
- Promoter holding has decreased over last 3 years: -51.1%
Technical Indicators
Oscillators
Neutral
Overall
Bearish
Moving Averages
Bearish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 12.14% · Jun 2026
Quarterly Results
| Particulars | Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 23.47 | 52.24 | 134 | 101 |
| Expenses | 19.29 | 48.69 | 124 | 88.69 |
| Operating Profit | 4.18 | 3.55 | 10.19 | 12.25 |
| OPM % | 17.81% | 6.8% | 7.6% | 12.14% |
| Other Income | 0.04 | 0.04 | 0.1 | 0.14 |
| Interest | 0.27 | 0.33 | 1.09 | 1.18 |
| Depreciation | 0.1 | 0.12 | 0.86 | 0.86 |
| PBT | 3.85 | 3.14 | 8.34 | 10.35 |
| Tax % | 28.57% | 24.52% | 7.91% | 8.99% |
| Net Profit | 2.74 | 2.36 | 7.68 | 9.42 |
| EPS (₹) | 2.79 | 2.19 | 1.82 | 2.15 |
Profit & Loss
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 64 | 250 |
| Expenses | 51 | 229 |
| Operating Profit | 13 | 21 |
| OPM % | 20% | 8% |
| Other Income | 0 | 0 |
| Interest | 1 | 2 |
| Depreciation | 0 | 1 |
| PBT | 12 | 18 |
| Tax % | 25% | 17% |
| Net Profit | 9 | 15 |
| EPS (₹) | 9.08 | 3.48 |
| Div. Payout % | 0% | 0% |
Balance Sheet
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity Capital | 10 | 42 |
| Reserves | 26 | 292 |
| Borrowings | 13 | 49 |
| Other Liabilities | 14 | 136 |
| Total Liabilities | 63 | 519 |
| Fixed Assets | 11 | 64 |
| CWIP | 0 | 0 |
| Investments | 0 | 203 |
| Other Assets | 52 | 251 |
| Total Assets | 63 | 519 |
Cash Flow
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | -13 | -18 |
| Investing | -8 | -2 |
| Financing | 3 | 3 |
| Net Cash Flow | -17 | -17 |
| Free Cash Flow | -18 | -19 |
| CFO/EBITDA | -96 | -80 |
Ratios
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Debtor Days | 157 | 229 |
| Inventory Days | 112 | 112 |
| Days Payable | 82 | 206 |
| Cash Conversion Cycle | 187 | 135 |
| Working Capital Days | 97 | 113 |
| ROCE % | — | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Astal Laboratories insights
60 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Astal Laboratories
What does Astal Laboratories Ltd do?
Where is Astal Laboratories Ltd (ASTALLTD) listed?
Which sector does Astal Laboratories Ltd belong to?
What is the market capitalisation of Astal Laboratories Ltd?
What is the PE ratio of Astal Laboratories Ltd?
What is the 52-week high and low of Astal Laboratories Ltd?
What is the Return on Equity (ROE) of Astal Laboratories Ltd?
Company Information
Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/512600.md for Astal Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.